XI YANG^1,5,#, HUIXIAN WU^2,3,#, CHAO XIONG^4,#, BO ZHAO¹, MEILIAN LIU¹, JIE QIN⁶, MEI DENG^1,2,3,*

BIOCELL, Vol.47, No.5, pp. 1021-1037, 2023, DOI:10.32604/biocell.2023.027103

Abstract Background: Cytochrome b561 (CYB561) plays a critical role in neuroendocrine function, cardiovascular regulation, and tumor growth; however, the prognostic value of CYB561 in patients with breast cancer and the relationship between CYB561 expression and immune infiltration in breast cancer remain unclear. Methods: The mRNA expression and clinical data of patients with breast cancer were obtained from The Cancer Genome Atlas database. Functional enrichment analysis was used to explore underlying biological functions associated with CYB561. The methylation status of CYB561 was analyzed using the MethSurv database. The enrichment score of immune cell infiltration for CYB561 in breast cancer was calculated using… More >

GANG WANG^#, MINGPING QIAN^#, WEI JIAN, JUHANG CHU, YIXIANG HUANG^*

Oncology Research, Vol.31, No.1, pp. 63-70, 2023, DOI:10.32604/or.2022.028168

Abstract Circular RNA (circRNA), as a newly discovered non-coding RNA with important regulatory potential, is closely related to the occurrence and progression of various tumors. This study aimed to investigate has_circ_0000069 expression in breast cancer and its influence on cellular activities. Using real-time quantitative polymerase chain reaction, has_circ_0000069 levels were measured in 137 pairs of tissue specimens, as well as cancer cell lines. The cellular activities of cell lines were determined by cell counting kit-8 (CCK-8) and Transwell assays. The potential targeting miRNAs were predicted and verified using an online database and dual-luciferase reporter assay. Has_circ_0000069 was highly expressed in breast… More >

QING GAO^1,#, YUJING SHI^2,#, YUANYUAN SUN^1,#, SHU ZHOU¹, ZEYUAN LIU³, XINCHEN SUN^1,*, XIAOKE DI^1,*

Oncology Research, Vol.31, No.1, pp. 35-61, 2023, DOI:10.32604/or.2022.028193

Abstract Aging is highly associated with tumor formation and progression. However, little research has explored the association of aging-related lncRNAs (ARLs) with the prognosis and tumor immune microenvironment (TIME) of head and neck squamous cell carcinoma (HNSCC). RNA sequences and clinicopathological data of HNSCC patients and normal subjects were downloaded from The Cancer Genome Atlas. In the training group, we used Pearson correlation, univariate Cox regression, least absolute shrinkage/selection operator regression analyses, and multivariate Cox regression to build a prognostic model. In the test group, we evaluated the model. Multivariate Cox regression was done to screen out independent prognostic factors, with… More >

YUNAN MAO^1,#, JINZE SHEN^1,#, LI FANG², FENG ZHU^1,*, SHIWEI DUAN^1,*

Oncology Research, Vol.31, No.1, pp. 1-12, 2023, DOI:10.32604/or.2022.027359

Abstract miRNAs are endogenous small RNAs that are important regulators of gene expression. miR-1294 was found to be significantly down-regulated in 15 cancers and regulated by 21 upstream regulators. miR-1294 affects the proliferation, migration, invasion, and apoptosis of cancer cells. The target genes of miR-1294 are involved in the PI3K/AKT/mTOR, RAS, and JAK/STAT signaling pathways. Six target genes of miR-1294 are the targets of a variety of drugs. Low expression of miR-1294 is associated with resistance to cisplatin and TMZ and a poorer prognosis in patients with ESCC, GC, EOC, PDAC, or NSCLC. Therefore, this work outlines the molecular mechanisms and… More >

HAOTONG SUN^1,2, HEYING WANG^1,3, XIN LI^1,2, YANJIE HAO^1,2, JUN LING^1,2, HUAN WANG^1,2, FEIMIAO WANG^1,2, FANG XU^1,2,*

BIOCELL, Vol.47, No.3, pp. 607-618, 2023, DOI:10.32604/biocell.2023.026445

Abstract Background: Colon adenocarcinoma (COAD) is the second leading cause of cancer death worldwide thus, identification of COAD biomarkers is critical. Mitotic Arrest Deficient 2 Like 2 (MAD2L2) is a key factor in mammalian DNA damage repair and is highly expressed in many malignant tumors. This is a comprehensive study of MAD2L2 expression, its diagnostic value, prognostic analysis, potential biological function, and impact on the immune system of patients with COAD. Methods: Gene expression, clinical relevance, prognostic analysis, diagnostic value, GO/KEGG cluster analysis, data obtained from TCGA, and bioinformatics statistical analysis were performed using the R package. Immune responses to MAD2L2… More >

ZHANSHU LIU¹, XI HUANG^2,*

BIOCELL, Vol.47, No.3, pp. 593-605, 2023, DOI:10.32604/biocell.2023.024148

Abstract Purpose: Iron metabolism maintains the balance between iron absorption and excretion. Abnormal iron metabolism can cause numerous diseases, including tumor. This study determined the iron metabolism-related genes (IMRGs) signature that can predict the prognosis of acute myeloid leukemia (AML). The roles of these genes in the immune microenvironment were also explored. Methods: A total of 514 IMRGs were downloaded from the Molecular Characteristics Database (MSigDB). IMRGs related to AML prognosis were identified using Cox regression and LASSO analyses and were used to construct the risk score model. AML patients were stratified into high-risk groups (cluster 1) and low-risk groups (cluster… More >

Hua Yang^*

Oncologie, Vol.24, No.4, pp. 835-863, 2022, DOI:10.32604/oncologie.2022.026447

Abstract Background: Epithelial ovarian cancer (EOC) is the deadliest malignancy among the gynecologic tumors, and ovarian serous cystadenocarcinoma (OV) is the dominant histological type. Ferroptosis is a novel iron-dependent, programmed form of cell death, and agents that trigger ferroptosis may constitute potential anti-cancer therapies. Materials and Methods: We herein extracted the genes that participate in the process of ferroptosis from the online FerrDb database to create a ferroptosis-related genome (FRG), and then comprehensively analyzed the relationship between the mRNA expression of each gene and the clinicopathologic features of The Cancer Genome Atlas (TCGA)-OV cohort. Results: We found that most of the… More >

Lei Hu^1,2,#, Meng Chen^2,3,#, Haiming Dai^2,3,4, Hongzhi Wang^2,3,4,*, Wulin Yang^2,3,4,*

Oncologie, Vol.24, No.4, pp. 803-822, 2022, DOI:10.32604/oncologie.2022.026419

Abstract Background and Aim: Hundreds of consistently altered metabolic genes have been identified in breast cancer (BC), but their prognostic value remains to be explored. Therefore, we aimed to build a prediction model based on metabolism-related genes (MRGs) to guide BC prognosis. Methods: Current work focuses on constructing a novel MRGs signature to predict the prognosis of BC patients using MRGs derived from the Virtual Metabolic Human (VMH) database, and expression profiles and clinicopathological data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Results: The 3-MRGs-signature constructed by SERPINA1, QPRT and PXDNL was found to be an… More >

Lina Tang^1,2, Haiyan Hu², Yan Zhou², Yujing Huang², Yonggang Wang², Yawen Zhang², Jinrong Liang², Zhenxin Wang^1,*

Oncologie, Vol.24, No.4, pp. 913-925, 2022, DOI:10.32604/oncologie.2022.026296

Abstract Objective: To investigate the expression of alpha–smooth muscle actin (ACTA2) in osteosarcoma tissues and its relationship with prognosis. Methods: Prognostic analysis of lung metastasis–related genes in osteosarcoma using the TCGA database. Single-cell sequencing detected the expression of ACTA2 in 11 osteosarcoma tissues. Paraf- fin-embedded tissues of 74 osteosarcoma patients treated at the Sixth People’s Hospital of Shanghai Jiao Tong University from 2014 to 2019 were collected, and tissue microarrays were prepared. ACTA2 expression was detected and scored by immunohistochemistry. According to the median value of the ACTA2 histochemical score, 74 patients were divided into two groups, the high-expression group and… More >

Xue Cui^1,2, Min Peng², Honglei Chen^1,*

Oncologie, Vol.24, No.4, pp. 665-678, 2022, DOI:10.32604/oncologie.2022.023641

Abstract The emergence of tumor immunotherapy, especially immune checkpoint inhibitors (ICIs), has brought new life to cancer treatment, and ICIs can effectively treat various tumors. Among the immune anti-cancer therapies, PD-1 is undoubtedly the hot target after CTLA-4, but due to the ineffectiveness of PD-1 in treating certain tumors, researchers have shifted their focus to other combination targets, such as LAG-3, TIM3, IDO-1, etc. One of these promising targets is LAG-3, a target with multiple clinical trials, which has increasingly shown to be an inhibitory co-receptor that plays a vital role in autoimmunity, cancer immunity, and anti-infection immunity. Immune combination therapy… More >